Table 1.
Clinical characteristics of COVID-19 autopsy cohort
| Diabetic patients (N = 37) |
Non-diabetic patients (N = 60) |
P | |
|---|---|---|---|
| Age, years | 65.9 ± 10.9 | 69.3 ± 9.4 | 0.107 |
| Male, n (%) | 23 (62.2) | 37 (61.7) | 0.515 |
| BMI, kg/m2 | 28.9 ± 6.4 | 26.2 ± 1.9 | 0.019 |
| Duration symptoms, days | 14.3 ± 1.9 | 15.1 ± 2.1 | 0.065 |
| Duration Hospitalization, days | 11.3 ± 1.1 | 9.7 ± 1.2 | 0.002 |
| Dyslipidemia, n (%) | 7 (15.2) | 30 (23.7) | 0.181 |
| Hypertension, n (%) | 23 (62.2) | 36 (60.0) | 0.502 |
| Obesity, n (%) | 15 (40.5) | 20 (33.3) | 0.307 |
| Cardiovascular disease, n (%) | 12 (32.4) | 21 (35.0) | 0.322 |
| COPD, n (%) | 22 (59.5) | 34 (56.7) | 0.478 |
| Smoking, n (%) | 8 (21.6) | 12 (20.0) | 0.522 |
| Patients with SARS-COV-2 infected cardiomyocytes, n (%) | 30 (81.1) | 17 (28.3) | 0.001 |
| Patients with SARS-COV-2 infected endothelial cells, n (%) | 10 (27.0) | 22 (36.7) | 0.225 |
| Patients with SARS-COV-2 infected macrophages, n (%) | 20 (54.1) | 41 (68.3) | 0.116 |
| Covid-19 drug therapy | |||
| Antiviral (%) | 37 (100) | 60 (100) | / |
| Antibiotics (%) | 32 (86.5) | 51 (85) | 0.396 |
| Chinidine (%) | 30 (81.1) | 50 (83.3) | 0.512 |
| Glucocorticoids (%) | 29 (78.4) | 49 (81.7) | 0.215 |
| Tocilizumab (%) | 4 (10.8) | 6 (10) | 0.510 |
| Oxygen inhalation (%) | 31 (83.8) | 50 (83.3) | 0.256 |
Data are means ± SD or n (%)
BMI body mass index, COPD chronic obstructive pulmonary disease, SARS-COV-2 severe acute respiratory syndrome coronavirus 2